Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 332

1.

Antimicrobial resistance in Clostridium difficile ribotype 017.

Imwattana K, Knight DR, Kullin B, Collins DA, Putsathit P, Kiratisin P, Riley TV.

Expert Rev Anti Infect Ther. 2019 Dec 6:1-9. doi: 10.1080/14787210.2020.1701436. [Epub ahead of print]

PMID:
31800331
2.

Clostridium difficile and One Health.

Lim SC, Knight DR, Riley TV.

Clin Microbiol Infect. 2019 Nov 1. pii: S1198-743X(19)30559-2. doi: 10.1016/j.cmi.2019.10.023. [Epub ahead of print] Review.

PMID:
31682985
3.

Different molecular characteristics and antimicrobial resistance profiles of Clostridium difficile in the Asia-Pacific region.

Luo Y, Cheong E, Bian Q, Collins DA, Ye J, Shin JH, Yam WC, Takata T, Song X, Wang X, Kamboj M, Gottlieb T, Jiang J, Riley TV, Tang YW, Jin D.

Emerg Microbes Infect. 2019;8(1):1553-1562. doi: 10.1080/22221751.2019.1682472.

4.

Molecular epidemiology of Clostridium difficile isolated from piglets.

Putsathit P, Neela VK, Joseph NMS, Ooi PT, Ngamwongsatit B, Knight DR, Riley TV.

Vet Microbiol. 2019 Oct;237:108408. doi: 10.1016/j.vetmic.2019.108408. Epub 2019 Sep 4.

PMID:
31585650
5.

Adaptation of host transmission cycle during Clostridium difficile speciation.

Kumar N, Browne HP, Viciani E, Forster SC, Clare S, Harcourt K, Stares MD, Dougan G, Fairley DJ, Roberts P, Pirmohamed M, Clokie MRJ, Jensen MBF, Hargreaves KR, Ip M, Wieler LH, Seyboldt C, Norén T, Riley TV, Kuijper EJ, Wren BW, Lawley TD.

Nat Genet. 2019 Sep;51(9):1315-1320. doi: 10.1038/s41588-019-0478-8. Epub 2019 Aug 12.

PMID:
31406348
6.

Microbiological evaluation of the ability of the DEKO-190 Washer/Disinfector to remove Clostridium difficile spores from bedpan surfaces.

Collins DA, Carson KC, Riley TV.

Infect Dis Health. 2019 Nov;24(4):208-211. doi: 10.1016/j.idh.2019.07.001. Epub 2019 Aug 3.

PMID:
31387799
7.

In silico, in vitro and in vivo analysis of putative virulence factors identified in large clostridial toxin-negative, binary toxin- producing C. difficile strains.

Androga GO, Knight DR, Hutton ML, Mileto SJ, James ML, Evans C, Lyras D, Chang BJ, Foster NF, Riley TV.

Anaerobe. 2019 Aug 1:102083. doi: 10.1016/j.anaerobe.2019.102083. [Epub ahead of print]

PMID:
31377188
8.

Cost-effectiveness of an environmental cleaning bundle for reducing healthcare associated infections.

White NM, Barnett AG, Hall L, Mitchell BG, Farrington A, Halton K, Paterson DL, Riley TV, Gardner A, Page K, Gericke CA, Graves N.

Clin Infect Dis. 2019 Jul 30. pii: ciz717. doi: 10.1093/cid/ciz717. [Epub ahead of print]

PMID:
31359053
9.

Genomic Delineation of Zoonotic Origins of Clostridium difficile.

Knight DR, Riley TV.

Front Public Health. 2019 Jun 20;7:164. doi: 10.3389/fpubh.2019.00164. eCollection 2019. Review.

10.

Phenotypic characterisation of Clostridium difficile PCR ribotype 251, an emerging multi-locus sequence type clade 2 strain in Australia.

Hong S, Knight DR, Chang B, Carman RJ, Riley TV.

Anaerobe. 2019 Jun 28:102066. doi: 10.1016/j.anaerobe.2019.06.019. [Epub ahead of print]

PMID:
31260740
11.

High prevalence of Clostridium difficile in soil, mulch and lawn samples from the grounds of Western Australian hospitals.

Perumalsamy S, Putsathit P, Riley TV.

Anaerobe. 2019 Jun 28:102065. doi: 10.1016/j.anaerobe.2019.06.018. [Epub ahead of print]

PMID:
31260739
12.

Clostridium difficile ribotype 017 - characterization, evolution and epidemiology of the dominant strain in Asia.

Imwattana K, Knight DR, Kullin B, Collins DA, Putsathit P, Kiratisin P, Riley TV.

Emerg Microbes Infect. 2019;8(1):796-807. doi: 10.1080/22221751.2019.1621670. Review.

13.

Recurrence of Clostridium difficile infection in the Western Australian population.

Alfayyadh M, Collins DA, Tempone S, McCann R, Armstrong PK, Riley TV, Cook A.

Epidemiol Infect. 2019 Jan;147:e153. doi: 10.1017/S0950268819000499.

14.

Evolutionary and Genomic Insights into Clostridioides difficile Sequence Type 11: a Diverse Zoonotic and Antimicrobial-Resistant Lineage of Global One Health Importance.

Knight DR, Kullin B, Androga GO, Barbut F, Eckert C, Johnson S, Spigaglia P, Tateda K, Tsai PJ, Riley TV.

MBio. 2019 Apr 16;10(2). pii: e00446-19. doi: 10.1128/mBio.00446-19.

15.

Status of vaccine research and development for Clostridium difficile.

Riley TV, Lyras D, Douce GR.

Vaccine. 2019 Nov 28;37(50):7300-7306. doi: 10.1016/j.vaccine.2019.02.052. Epub 2019 Mar 19.

PMID:
30902484
16.

Cationic biaryl 1,2,3-triazolyl peptidomimetic amphiphiles targeting Clostridioides (Clostridium) difficile: Synthesis, antibacterial evaluation and an in vivo C. difficile infection model.

Tague AJ, Putsathit P, Hutton ML, Hammer KA, Wales SM, Knight DR, Riley TV, Lyras D, Keller PA, Pyne SG.

Eur J Med Chem. 2019 May 15;170:203-224. doi: 10.1016/j.ejmech.2019.02.068. Epub 2019 Mar 1.

PMID:
30901686
17.

High prevalence and diversity of tcdA-negative and tcdB-positive, and non-toxigenic, Clostridium difficile in Thailand.

Imwattana K, Wangroongsarb P, Riley TV.

Anaerobe. 2019 Jun;57:4-10. doi: 10.1016/j.anaerobe.2019.03.008. Epub 2019 Mar 9.

PMID:
30862468
18.

An environmental cleaning bundle and health-care-associated infections in hospitals (REACH): a multicentre, randomised trial.

Mitchell BG, Hall L, White N, Barnett AG, Halton K, Paterson DL, Riley TV, Gardner A, Page K, Farrington A, Gericke CA, Graves N.

Lancet Infect Dis. 2019 Apr;19(4):410-418. doi: 10.1016/S1473-3099(18)30714-X. Epub 2019 Mar 8.

PMID:
30858014
19.

Cationic biaryl 1,2,3-triazolyl peptidomimetic amphiphiles: synthesis, antibacterial evaluation and preliminary mechanism of action studies.

Tague AJ, Putsathit P, Hammer KA, Wales SM, Knight DR, Riley TV, Keller PA, Pyne SG.

Eur J Med Chem. 2019 Apr 15;168:386-404. doi: 10.1016/j.ejmech.2019.02.013. Epub 2019 Feb 13.

PMID:
30831407
20.

Clostridium difficile in Asia: Opportunities for One Health Management.

Collins DA, Riley TV.

Trop Med Infect Dis. 2018 Dec 28;4(1). pii: E7. doi: 10.3390/tropicalmed4010007. Review.

21.

A series of three cases of severe Clostridium difficile infection in Australia associated with a binary toxin producing clade 2 ribotype 251 strain.

Wehrhahn MC, Keighley C, Kurtovic J, Knight DR, Hong S, Hutton ML, Lyras D, Wang Q, Leong R, Borody T, Edye M, Riley TV.

Anaerobe. 2019 Feb;55:117-123. doi: 10.1016/j.anaerobe.2018.11.009. Epub 2018 Nov 27.

PMID:
30500477
22.

Natural products show diverse mechanisms of action against Clostridium difficile.

Roshan N, Riley TV, Knight DR, Steer JH, Hammer KA.

J Appl Microbiol. 2019 Feb;126(2):468-479. doi: 10.1111/jam.14152. Epub 2018 Dec 26.

PMID:
30412324
23.

Effect of natural products on the production and activity of Clostridium difficile toxins in vitro.

Roshan N, Riley TV, Knight DR, Hammer KA.

Sci Rep. 2018 Oct 24;8(1):15735. doi: 10.1038/s41598-018-33954-2.

24.

Genomic Analysis of Multiresistant Staphylococcus capitis Associated with Neonatal Sepsis.

Carter GP, Ussher JE, Da Silva AG, Baines SL, Heffernan H, Riley TV, Broadbent R, van der Linden A, Lee J, Monk IR, Stinear TP, Howden BP, Williamson DA.

Antimicrob Agents Chemother. 2018 Oct 24;62(11). pii: e00898-18. doi: 10.1128/AAC.00898-18. Print 2018 Nov.

25.

Antimicrobial resistance in large clostridial toxin-negative, binary toxin-positive Clostridium difficile ribotypes.

Androga GO, Knight DR, Lim SC, Foster NF, Riley TV.

Anaerobe. 2018 Dec;54:55-60. doi: 10.1016/j.anaerobe.2018.07.007. Epub 2018 Jul 25.

PMID:
30053486
26.

Diverse bacterial species contribute to antibiotic-associated diarrhoea and gastrointestinal damage.

Larcombe S, Hutton ML, Riley TV, Abud HE, Lyras D.

J Infect. 2018 Nov;77(5):417-426. doi: 10.1016/j.jinf.2018.06.006. Epub 2018 Jun 30.

PMID:
29964142
27.

Antimicrobial susceptibility of Clostridium difficile isolated from food and environmental sources in Western Australia.

Lim SC, Androga GO, Knight DR, Moono P, Foster NF, Riley TV.

Int J Antimicrob Agents. 2018 Sep;52(3):411-415. doi: 10.1016/j.ijantimicag.2018.05.013. Epub 2018 May 23.

PMID:
29802886
28.

Spectrum of antibacterial activity and mode of action of a novel tris-stilbene bacteriostatic compound.

Man NYT, Knight DR, Stewart SG, McKinley AJ, Riley TV, Hammer KA.

Sci Rep. 2018 May 2;8(1):6912. doi: 10.1038/s41598-018-25080-w.

29.

Effects of natural products on several stages of the spore cycle of Clostridium difficile in vitro.

Roshan N, Riley TV, Hammer KA.

J Appl Microbiol. 2018 Sep;125(3):710-723. doi: 10.1111/jam.13889. Epub 2018 Jun 26.

PMID:
29675852
30.

Clostridium difficile Guidelines.

Collins DA, Riley TV.

Clin Infect Dis. 2018 Oct 30;67(10):1639. doi: 10.1093/cid/ciy249. No abstract available.

PMID:
29590322
31.

High Prevalence of Toxigenic and Nontoxigenic Clostridium difficile Strains in Malaysia.

Riley TV, Collins DA, Karunakaran R, Kahar MA, Adnan A, Hassan SA, Zainul NH, Rustam FRM, Wahab ZA, Ramli R, Lee YY, Hassan H.

J Clin Microbiol. 2018 May 25;56(6). pii: e00170-18. doi: 10.1128/JCM.00170-18. Print 2018 Jun.

32.

Changes in knowledge and attitudes of hospital environmental services staff: The Researching Effective Approaches to Cleaning in Hospitals (REACH) study.

Mitchell BG, White N, Farrington A, Allen M, Page K, Gardner A, Halton K, Riley TV, Gericke CA, Paterson DL, Graves N, Hall L.

Am J Infect Control. 2018 Sep;46(9):980-985. doi: 10.1016/j.ajic.2018.02.003. Epub 2018 Mar 14.

33.

Evaluation of the Cepheid® Xpert®C. difficile binary toxin (BT) diagnostic assay.

McGovern AM, Androga GO, Moono P, Collins DA, Foster NF, Chang BJ, Riley TV.

Anaerobe. 2018 Jun;51:12-16. doi: 10.1016/j.anaerobe.2018.03.004. Epub 2018 Mar 11.

PMID:
29534914
34.

1,2,4-Oxadiazole antimicrobials act synergistically with daptomycin and display rapid kill kinetics against MDR Enterococcus faecium.

Carter GP, Harjani JR, Li L, Pitcher NP, Nong Y, Riley TV, Williamson DA, Stinear TP, Baell JB, Howden BP.

J Antimicrob Chemother. 2018 Jun 1;73(6):1562-1569. doi: 10.1093/jac/dky064.

PMID:
29518208
35.

The Epidemiology of Clostridium difficile Infection in Japan: A Systematic Review.

Riley TV, Kimura T.

Infect Dis Ther. 2018 Mar;7(1):39-70. doi: 10.1007/s40121-018-0186-1. Epub 2018 Feb 13. Review.

36.

Non-conventional antimicrobial and alternative therapies for the treatment of Clostridium difficile infection.

Roshan N, Hammer KA, Riley TV.

Anaerobe. 2018 Feb;49:103-111. doi: 10.1016/j.anaerobe.2018.01.003. Epub 2018 Jan 6. Review.

PMID:
29309845
37.

Zoonotic Transfer of Clostridium difficile Harboring Antimicrobial Resistance between Farm Animals and Humans.

Knetsch CW, Kumar N, Forster SC, Connor TR, Browne HP, Harmanus C, Sanders IM, Harris SR, Turner L, Morris T, Perry M, Miyajima F, Roberts P, Pirmohamed M, Songer JG, Weese JS, Indra A, Corver J, Rupnik M, Wren BW, Riley TV, Kuijper EJ, Lawley TD.

J Clin Microbiol. 2018 Feb 22;56(3). pii: e01384-17. doi: 10.1128/JCM.01384-17. Print 2018 Mar.

38.

High prevalence of Clostridium difficile on retail root vegetables, Western Australia.

Lim SC, Foster NF, Elliott B, Riley TV.

J Appl Microbiol. 2018 Feb;124(2):585-590. doi: 10.1111/jam.13653.

PMID:
29193458
39.

Prevalence of binary toxin positive Clostridium difficile in diarrhoeal humans in the absence of epidemic ribotype 027.

McGovern AM, Androga GO, Knight DR, Watson MW, Elliott B, Foster NF, Chang BJ, Riley TV.

PLoS One. 2017 Nov 8;12(11):e0187658. doi: 10.1371/journal.pone.0187658. eCollection 2017.

40.

Clostridium difficile infection in the Lao People's Democratic Republic: first isolation and review of the literature.

Cheong E, Roberts T, Rattanavong S, Riley TV, Newton PN, Dance DAB.

BMC Infect Dis. 2017 Sep 21;17(1):635. doi: 10.1186/s12879-017-2737-6. Review.

41.

Prevalence of Clostridium difficile infection and colonization in a tertiary hospital and elderly community of North-Eastern Peninsular Malaysia.

Zainul NH, Ma ZF, Besari A, Siti Asma H, Rahman RA, Collins DA, Hamid N, Riley TV, Lee YY.

Epidemiol Infect. 2017 Oct;145(14):3012-3019. doi: 10.1017/S0950268817002011. Epub 2017 Sep 11.

PMID:
28891459
42.

Epidemiology of Clostridium difficile in infants in Oxfordshire, UK: Risk factors for colonization and carriage, and genetic overlap with regional C. difficile infection strains.

Stoesser N, Eyre DW, Quan TP, Godwin H, Pill G, Mbuvi E, Vaughan A, Griffiths D, Martin J, Fawley W, Dingle KE, Oakley S, Wanelik K, Finney JM, Kachrimanidou M, Moore CE, Gorbach S, Riley TV, Crook DW, Peto TEA, Wilcox MH, Walker AS; Modernising Medical Microbiology Informatics Group (MMMIG).

PLoS One. 2017 Aug 16;12(8):e0182307. doi: 10.1371/journal.pone.0182307. eCollection 2017.

43.

Community-associated Clostridium difficile infection in emergency department patients in Western Australia.

Collins DA, Selvey LA, Celenza A, Riley TV.

Anaerobe. 2017 Dec;48:121-125. doi: 10.1016/j.anaerobe.2017.08.008. Epub 2017 Aug 12.

PMID:
28807622
44.

Aboriginal and non-Aboriginal children in Western Australia carry different serotypes of pneumococci with different antimicrobial susceptibility profiles.

Dunne EM, Carville K, Riley TV, Bowman J, Leach AJ, Cripps AW, Murphy D, Jacoby P, Lehmann D; Kalgoorlie Otitis Media Research Project Team.

Pneumonia (Nathan). 2016 Sep 5;8:15. doi: 10.1186/s41479-016-0015-9. eCollection 2016.

45.

Prevalence and molecular epidemiology of Clostridium difficile infection in Indonesia.

Collins DA, Gasem MH, Habibie TH, Arinton IG, Hendriyanto P, Hartana AP, Riley TV.

New Microbes New Infect. 2017 May 4;18:34-37. doi: 10.1016/j.nmni.2017.04.006. eCollection 2017 Jul.

46.

Antimicrobial susceptibility of Clostridium difficile isolated in Thailand.

Putsathit P, Maneerattanaporn M, Piewngam P, Knight DR, Kiratisin P, Riley TV.

Antimicrob Resist Infect Control. 2017 Jun 8;6:58. doi: 10.1186/s13756-017-0214-z. eCollection 2017.

47.

Correction for Cairns et al., "Comparative Genome Analysis and Global Phylogeny of the Toxin Variant Clostridium difficile PCR Ribotype 017 Reveals the Evolution of Two Independent Sublineages".

Cairns MD, Preston MD, Hall CL, Gerding DN, Hawkey PM, Kato H, Kim H, Kuijper EJ, Lawley TD, Pituch H, Reid S, Kullin B, Riley TV, Solomon K, Tsai PJ, Weese JS, Stabler RA, Wren BW.

J Clin Microbiol. 2017 Jun;55(6):1971. doi: 10.1128/JCM.00487-17. No abstract available.

48.

Comparison of two environmental sampling tools for the detection of Clostridium difficile spores on hard bathroom surfaces in the hospital setting.

Engelhardt NEP, Foster NF, Hong S, Riley TV, McGechie DB.

J Hosp Infect. 2017 Jul;96(3):295-296. doi: 10.1016/j.jhin.2017.03.028. Epub 2017 Mar 31. No abstract available.

PMID:
28495188
49.

Antimicrobial activity of natural products against Clostridium difficile in vitro.

Roshan N, Riley TV, Hammer KA.

J Appl Microbiol. 2017 Jul;123(1):92-103. doi: 10.1111/jam.13486. Epub 2017 Jun 8.

PMID:
28489336
50.

Human Clostridium difficile infection caused by a livestock-associated PCR ribotype 237 strain in Western Australia.

Mc Govern AM, Foster NF, Pereira LA, Knight DR, Elliott B, Chang BJ, Riley TV.

JMM Case Rep. 2016 Aug 30;3(4):e005062. doi: 10.1099/jmmcr.0.005062. eCollection 2016 Aug.

Supplemental Content

Loading ...
Support Center